UNSPSC 51351706: Arzoxifene hydrochloride

This classification denotes a selective estrogen receptor modulator with the molecular formula C28H29NO4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FU88PI0433, chemically known as benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl)ethoxy)phenoxy)-, hydrochloride but more generally known as arzoxifene hydrochloride, which bears US NIH Compound Identifier 179338. The base compound, Arzoxifene, most often comes in base and hydrochloride forms.

Most nations, for tariff and trade purposes, schedule arzoxifene hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ARZOXIFENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Arzoxifene hydrochloride bears US NLM identifiers UMLS ID C0950979 and NCI Concept Code C2460. SMILES: COC1CCC(CC1)C2C(C3CCC(CC3S2)O)OC4CCC(CC4)OCCN5CCCCC5.CL.

UNSPSC 51351706 Arzoxifene hydrochloride is a Commodity code representing pharmaceutical active ingredients and finished-dose products procured by state and local health systems, correctional facilities, and public healthcare programs. State and local governments buy under this code when establishing master contracts or cooperative purchasing agreements for specific generic pharmaceuticals and over-the-counter medications through authorized drug wholesalers, with pricing and product availability negotiated at the manufacturer or primary-distributor level. Scope includes negotiating National Drug Codes (NDCs), unit pricing across multiple packaging configurations, compliance certifications (cGMP, DSCSA, FDA), and electronic data interchange capability to integrate with state pharmacy benefit management and procurement systems. Issuing bodies soliciting under this code include state health and human services departments, state departments of administration, and multistate cooperative purchasing alliances that aggregate demand across participating states and local jurisdictions—often administered by a lead state purchasing office. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products spanning participating state and local government facilities in Minnesota and Oregon. The solicitation requires vendors to maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with functional chargeback systems; submit detailed product specifications and pricing in CSV format; hold commercial general liability of $5 million per occurrence and network security and privacy liability of $2 million; and comply with performance penalties ranging from $200 to $1,500 per violation. Awarded vendors' products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. The evaluation emphasizes price competitiveness (75 percent weight), fixed pricing commitment (10 percent), and administrative and technical compliance (15 percent combined). MMCAP reserves multi-award rights based on therapeutic considerations and member-specific needs. The RFP does not disclose specific award values or budget allocations.